Literature DB >> 18225583

Inhibition of MRP1 transport activity by phenolic and terpenic compounds isolated from Euphorbia species.

Olga Wesolowska1, Jerzy Wisniewski, Noélia Duarte, Maria-José U Ferreira, Krystyna Michalak.   

Abstract

BACKGROUND: A search for inhibitors of multidrug resistance (MDR)-associated protein 1 (MRP1) was performed among the compounds isolated from Euphorbia species, plants traditionally used in folk medicine.
MATERIALS AND METHODS: Fifteen compounds with terpenic or phenolic structures (macrocyclic and polycyclic diterpenes, coumarins, stilbenes and flavonoids) were isolated from the methanol extracts of Euphorbia lagascae and Euphorbia tuckeyana or obtained by derivatization. A functional test based on measuring the efflux of fluorescent MRP1 substrate (BCECF) from human erythrocytes was employed.
RESULTS: Effective MRP1 inhibitors were identified among the stilbenes (piceatannol and its derivatives) and the flavonoids (aromadendrin, naringenin and its derivatives).
CONCLUSION: Euphorbia species constitute a promising source of multidrug resistance modulators.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18225583

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Secondary Metabolites from Plants Inhibiting ABC Transporters and Reversing Resistance of Cancer Cells and Microbes to Cytotoxic and Antimicrobial Agents.

Authors:  Michael Wink; Mohamed L Ashour; Mahmoud Zaki El-Readi
Journal:  Front Microbiol       Date:  2012-04-23       Impact factor: 5.640

2.  E. fischeriana Root Compound Dpo Activates Antiviral Innate Immunity.

Authors:  Jingxuan Chen; Hongqiang Du; Shuang Cui; Tong Liu; Guang Yang; Huaping Sun; Weiwei Tao; Baoping Jiang; Li Yu; Fuping You
Journal:  Front Cell Infect Microbiol       Date:  2017-10-26       Impact factor: 5.293

Review 3.  Voltage-Gated Potassium Channel Kv1.3 as a Target in Therapy of Cancer.

Authors:  Andrzej Teisseyre; Anna Palko-Labuz; Kamila Sroda-Pomianek; Krystyna Michalak
Journal:  Front Oncol       Date:  2019-09-24       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.